Remove Biosimilars Remove Insurance Coverage and Processing Remove White Paper
article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence. Decentralising manufacturing has previously been seen as an “up-and-coming development” in the cell and gene therapy sector due to high costs associated with setting up these processes.

article thumbnail

DoH and Children’s National Hospital link for cell and gene therapy

Pharmaceutical Technology

This alliance seeks to bolster clinical trial capabilities through improved regulatory processes and data governance. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. They aim to develop patient-specific treatment protocols while ensuring adherence to rigorous international standards.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

RFK Jr’s mRNA funding halt signals “shift in US public health”

Pharmaceutical Technology

mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Shares of key sector players such as Moderna and BioNTech remain stable, with values reducing by 2.8% and increasing by 0.21% respectively, suggesting that investors still have hope for the modality.